A phase i study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 910-917

  Yoshino, Takayuki ^a   Yamazaki, Kentaro ^b   Yamaguchi, Kensei ^c   Doi, Toshihiko ^a   Boku, Narikazu ^b   Machida, Nozomu ^b   Onozawa, Yusuke ^b   Asayama, Masako ^a   Fujino, Tadahiro ^d   Ohtsu, Atsushi ^e  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d Sanofi KK ^*  (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Aflibercept (VEGF trap); FOLFIRI; Metastatic colorectal cancer; Phase I study; Vascular endothelial growth factor (VEGF)

Indexed keywords

AFLIBERCEPT; FLUOROURACIL; IRINOTECAN; LEVOLEUCOVORIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GINGIVITIS; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; IMMUNOGENICITY; JAPANESE; LEUKOPENIA; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, INTRAVENOUS; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880924850     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9895-6     Document Type: Article

References (25)

1. Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359-1364
2. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31
3. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
4. Gimbrone MA Jr, Leapman SB, Cotran RS et al (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136:261-276
5. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18
6. Dvorak HF, Dvorak AM, Manseau EJ, Wiberg L, Churchill WH (1979) Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst 62:1459-1472
7. Zhang HT, Craft P, Scott PA et al (1995) Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 87:213-219
8. Claffey KP, Robinson GS (1996) Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 15:165-176
9. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400
10. Holash J, Davis S, Papadopoulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398
11. Presta LG, Chen H, O'Connor SJ et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599
12. Fischer C, Mazzone M, Jonckx B, Carmeliet P (2008) FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8:942-956
13. Fischer C, Jonckx B, Mazzone M et al (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463-475
14. Jemal A, Thomas A, Murray T et al (2002) Colorectal cancer incidence, mortality and survival in South-east England between 1972 and 2001: Cancer statistics. CA Cancer J Clin 52:23-47
15. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics. CA Cancer J Clin 55:74-108
16. Saito H (2000) Colorectal cancer screening in Japan. Jpn J Cancer Clin 46:35-42
17. Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499-3506
18. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
19. Brookmeyer R, Crowley J (1982) A confidence interval for the median survival time. Biometrics 38:29-41
20. Lockhart AC, Rothenberg ML, Dupont J et al (2010) Phase I study of intravenous vascular endothelial growth factor Trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28:207-214
21. Van Cutsem E, Khayat D, Verslype C et al (2012) Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Eur J Cancer [Epub ahead of print]
22. Rudge JS, Holash I, Hylton D, Russell M, Jiang S, Leidich R (2007) VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 4:18363-18370
23. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237
24. Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853-860
25. Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706-4713